Home » Healthcare » Pharmaceuticals » Glaucoma Therapeutics Market

Glaucoma Therapeutics Market By Drug Class (Prostaglandins Analogs, Beta Blockers, Alpha-Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Fixed-Dose Combinations) – Growth, Future Prospects And Competitive Analysis 2017 – 2025

Price: $4999

Published: | Report ID: 6633 | Report Format : PDF

Market Insights

Glaucoma is a chronic, degenerative disorder that damages the eye’s optic nerve and may result in vision loss and blindness. Factors such as the high prevalence of glaucoma, technological advancement in diagnostic techniques, and rising treatment awareness are driving the market growth of glaucoma therapeutics globally.

The report titled “Glaucoma Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall glaucoma therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class and different geographical regions.

The report also includes sections on the competitive profiling of the leading players in the global glaucoma therapeutics market, appealing investment propositions, and market positioning of key manufacturers to assist strategic decision-makers. Other in-depth analysis provided in the report includes:

Geographically, the global glaucoma therapeutics market is studied for the following regional markets:

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • France
    • UK.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global glaucoma therapeutics market.

Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global glaucoma therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global glaucoma therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global glaucoma therapeutics market is segmented as follows:

  • Prostaglandins Analogs
  • Beta-blockers
  • Alpha-adrenergic Agonists
  • Carbonic anhydrase inhibitors
  • Combinations Medication

Glaucoma is a chronic, degenerative condition that damages the eye’s optic nerve, resulting in vision loss and blindness. Factors such as an increase in the prevalence of eye disorders, significant unmet medical needs, and the rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in 2016, prostaglandin analogs were the largest revenue-generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combinations such as Dorzolamide and Timolol, Latanoprost and Timolol, and Brimonidine and Timolol are widely used on the market.

Patient adherence is higher for fixed-dose combinations as they reduce the risk of medication washout and also decrease the daily topical preservative load. It is observed that beta blockers are the second-largest revenue-generating segment; they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increases in heart rate and blood pressure, which negatively impact the growth of the therapeutic glaucoma market.

For the purpose of this study, the global glaucoma therapeutics market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America dominated the glaucoma therapeutics market in terms of revenue, and it is anticipated that it will show steady growth during the forecast period of 2016–2024. Factors such as the rising geriatric population, the upsurge in funding by government agencies and private organizations in the healthcare system, the increasing incidence of eye disorders, and improved diagnostic techniques drive the growth of the glaucoma therapeutics market in North America. Europe is the second-largest revenue-generating regional market for glaucoma therapeutics. The U.K., Germany, and France are major revenue-contributing countries in Europe.

It is observed that the Middle East and Africa hold the smallest market share, and it is anticipated that they will show sluggish market growth during the forecast period. Comparatively lower costs of treatment medications hinder the market growth of glaucoma therapeutics in the Middle East and Africa. Currently, Asia Pacific is not a major revenue-generating segment. However, it is anticipated that it will experience significant growth during the forecast period. Factors such as an increasing population, continuous economic development, and developing healthcare infrastructure would contribute to market growth in Asia Pacific during the forecast period.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Glaucoma Therapeutics Market Snapshot
2.2 Global Glaucoma Therapeutics Market, by Drug Class, 2016 (US$ Bn)
2.3 Global Glaucoma Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Glaucoma Therapeutics Market Analysis
3.1 Global Glaucoma Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Significant Unmet Need
3.2.1.2 High prevalence of Eye Disorders
3.2.2 Challenges
3.2.2.1 Poor Patient Compliance
3.2.3 Opportunities
3.2.3.1 Increasing Treatment Awareness
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Glaucoma Therapeutics Market

Chapter 4 Global Glaucoma Therapeutics Market, by Drug Class
4.1 Overview
4.2 Prostaglandins Analogs
4.3 Beta Blockers
4.4 Alpha-adrenergic Agonists
4.5 Carbonic Anhydrase Inhibitors
4.6 Fixed-dose Combinations

Chapter 5 Global Glaucoma Therapeutics Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Aerie Pharmaceuticals
6.2 Akorn, Inc.
6.3 Allergan plc.
6.4 Bausch & Lomb Incorporated
6.5 Inotek Pharmaceuticals
6.6 Merck & Co., Inc.
6.7 Novartis AG
6.8 Pfizer Inc.
6.9 Santen Pharmaceuticals Co. Ltd
6.10 Teva Pharmaceuticals

List of Figures

FIG. 1 Glaucoma Therapeutics Market: Research Methodology
FIG. 2 Global Glaucoma Therapeutics Market, by Drug Class, 2016 (US$ Bn)
FIG. 3 Global Glaucoma Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Glaucoma Therapeutics Market, by Geography, 2016
FIG. 5 Global Prostaglandins Analogs Market for Glaucoma Therapeutics, 2015 – 2025 (US$ Bn)
FIG. 6 Global Beta Blockers Market for Glaucoma Therapeutics, 2015 – 2025 (US$ Bn)
FIG. 7 Global Alpha-adrenergic Agonists Market for Glaucoma Therapeutics, 2015 – 2025 (US$ Bn)
FIG. 8 Global Carbonic Anhydrase Inhibitors Market for Glaucoma Therapeutics, 2015 – 2025 (US$ Bn)
FIG. 9 Global Fixed-dose Combinations Market for Glaucoma Therapeutics, 2015 – 2025 (US$ Bn)
FIG. 10 Latin America Glaucoma Therapeutics Market, 2015 – 2025 (US$ Bn)
FIG. 11 Middle East and Africa Glaucoma Therapeutics Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Glaucoma Therapeutics Market
TABLE 2 Global Glaucoma Therapeutics Market, by Drug Class, 2015 – 2025 (US$ Bn)
TABLE 3 Global Glaucoma Therapeutics Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 4 North America Glaucoma Therapeutics Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 5 Europe Glaucoma Therapeutics Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 6 Asia Pacific Glaucoma Therapeutics Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Aerie Pharmaceuticals Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 8 Akorn, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 9 Allergan plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 10 Bausch & Lomb Incorporated: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 11 Inotek Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 12 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 13 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 14 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 15 Santen Pharmaceuticals Co. Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Glaucoma Therapeutics Market?

The market for Glaucoma Therapeutics Market is expected to reach US$ 5.67 Bn By 2025.

What is the Glaucoma Therapeutics Market CAGR?

The Glaucoma Therapeutics Market is expected to see significant CAGR growth over the coming years, at 2.8%.

What is the Forecast period considered for Glaucoma Therapeutics Market?

The report is forecasted from 2017-2025.

What is the base year considered for Glaucoma Therapeutics Market?

The base year of this report is 2016.

Who are the major players in this market?

Akorn, Inc., Allergan plc., Santen Pharmaceuticals Co. Ltd, Novartis AG, are some of the major players in the global market

Nanoparticle Formulation Market

Published:
Report ID: 41106

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN